Erythropoietin receptor is expressed in meningiomas and lower levels are associated with tumour recurrence

Küster, Onno; Simon, Perikles; Mittelbronn, Michel; Tabatabai, Ghazaleh; Hermann, C.; Strik, Herwig; Dietz, Klaus; Röser, Florian; Meyermann, Richard; Schittenhelm, Jens

doi:10.1111/j.1365-2990.2009.01021.x

Cited by 7 publications

(3 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Increased EPOR expression was also linked to reduced response to anti-cancer treatment (56, 57). While no or reduced EPOR expression was identified as prognostic factor for increased overall survival (178) and in contrast, also to increased cancer recurrence rate (183). Most of these studies did not characterize the subtype of EPOR isoforms, which is crucial for interpretation of the data, as indicated by Küster et al (183).…”

Section: Action Of Epo On Non-hematopoietic Cellsmentioning

confidence: 99%

Erythropoietin and Cancer: The Unintended Consequences of Anemia Correction

2014

View full text Add to dashboard Cite

Until 1990, erythropoietin (EPO) was considered to have a single biological purpose and action, the stimulation of red blood cell growth and differentiation. Slowly, scientific and medical opinion evolved, beginning with the discovery of an effect on endothelial cell growth in vitro and the identification of EPO receptors (EPORs) on neuronal cells. We now know that EPO is a pleiotropic growth factor that exhibits an anti-apoptotic action on numerous cells and tissues, including malignant ones. In this article, we present a short discussion of EPO, receptors involved in EPO signal transduction, and their action on non-hematopoietic cells. This is followed by a more detailed presentation of both pre-clinical and clinical data that demonstrate EPO’s action on cancer cells, as well as tumor angiogenesis and lymphangiogenesis. Clinical trials with reported adverse effects of chronic erythropoiesis-stimulating agents (ESAs) treatment as well as clinical studies exploring the prognostic significance of EPO and EPOR expression in cancer patients are reviewed. Finally, we address the use of EPO and other ESAs in cancer patients.

show abstract

Section: Action Of Epo On Non-hematopoietic Cellsmentioning

confidence: 99%

Erythropoietin and Cancer: The Unintended Consequences of Anemia Correction

2014

View full text Add to dashboard Cite

show abstract

“…Gehirns, wie z. B. pilozytische Astrozytome, anaplastische Ependymome, Medulloblastome, Neuroblastome (Batra et al 2003), Meningeome (Kuster et al 2009) und auch Glioblastome (Berdel et al 1991, Mohyeldin et al 2007, Yasuda et al 2003.…”

Section: Entsprechend Fanden Sich Auch Epo-und Epor-expression In Ver...unclassified

“…Wie bei systemischen Tumoren ist auch hier die Studienlage nicht eindeutig. Eine kürzlich veröffentlichte Studie an Meningeomen berichtete zuletzt, dass Tumoren mit einem niedrigen Niveau von EPOR-Expression ein höheres Risiko für Rezidive haben(Kuster et al 2009). an Glioblastomzelllinien Für die in dieser Arbeit untersuchten höhergradigen Tumoren astrozytären Ursprungs veröffentlichtenMohyeldin et al (2007) eine vielbeachtete Studie.…”

unclassified

Die Bedeutung von Erythropoietin und seinem Rezeptor für die Prognose humaner Glioblastome

Brunotte¹

View full text Add to dashboard Cite

Die Expression von EPO und EPOR in gesundem Hirngewebe zeigte im Kortexbereich sowie perivaskulär ebenfalls stets ein hohes Niveau, während in der weißen Substanz kaum EPO bzw. EPOR nachweisbar waren. 3.3.1.1 Beispielhafte Markierungen des EPO-Proteins (Vergrößerung in Klammern) Abbildung 11 Hohe EPO-Expression (200x) Abbildung 12 Hohe EPO-Expression (500x) Abbildung 13 Niedrige EPO-Expression (200x) Abbildung 14 Niedrige EPO-Expression (500x) Abbildung 15 Mitotische und mehrkernige Zellen (500x)

show abstract

Meningioma: Role of Erythropoietin Receptor in the Tumor Recurrence

Schittenhelm

Küster

2012

Tumors of the Central Nervous System, Volume 7

View full text Add to dashboard Cite

Erythropoietin receptor is expressed in meningiomas and lower levels are associated with tumour recurrence

Cited by 7 publications

References 54 publications

Erythropoietin and Cancer: The Unintended Consequences of Anemia Correction

Erythropoietin and Cancer: The Unintended Consequences of Anemia Correction

Die Bedeutung von Erythropoietin und seinem Rezeptor für die Prognose humaner Glioblastome

Meningioma: Role of Erythropoietin Receptor in the Tumor Recurrence

Contact Info

Product

Resources

About